- Home
- BLTE vs ACLS Comparison
BLTE vs ACLS Comparison
Compare BLTE & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- ACLS
- Stock Information
- Founded
- BLTE 2018
- ACLS 1995
- Country
- BLTE United States
- ACLS United States
- Employees
- BLTE N/A
- ACLS N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- ACLS Industrial Machinery/Components
- Sector
- BLTE Health Care
- ACLS Technology
- Exchange
- BLTE Nasdaq
- ACLS Nasdaq
- Market Cap
- BLTE 2.6B
- ACLS 2.6B
- IPO Year
- BLTE 2022
- ACLS 2000
- Fundamental
- Price
- BLTE $93.82
- ACLS $83.25
- Analyst Decision
- BLTE Strong Buy
- ACLS Buy
- Analyst Count
- BLTE 4
- ACLS 7
- Target Price
- BLTE $96.00
- ACLS $97.00
- AVG Volume (30 Days)
- BLTE 69.4K
- ACLS 773.5K
- Earning Date
- BLTE 11-11-2025
- ACLS 11-04-2025
- Dividend Yield
- BLTE N/A
- ACLS N/A
- EPS Growth
- BLTE N/A
- ACLS N/A
- EPS
- BLTE N/A
- ACLS 4.91
- Revenue
- BLTE N/A
- ACLS $896,089,000.00
- Revenue This Year
- BLTE N/A
- ACLS N/A
- Revenue Next Year
- BLTE N/A
- ACLS $5.53
- P/E Ratio
- BLTE N/A
- ACLS $16.98
- Revenue Growth
- BLTE N/A
- ACLS N/A
- 52 Week Low
- BLTE $49.00
- ACLS $40.40
- 52 Week High
- BLTE $93.59
- ACLS $102.93
- Technical
- Relative Strength Index (RSI)
- BLTE 77.42
- ACLS 45.19
- Support Level
- BLTE $88.00
- ACLS $78.80
- Resistance Level
- BLTE $91.92
- ACLS $85.53
- Average True Range (ATR)
- BLTE 3.16
- ACLS 3.09
- MACD
- BLTE 0.90
- ACLS -0.22
- Stochastic Oscillator
- BLTE 98.97
- ACLS 57.42
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.